Scientific advances made to date mark the era called the "end of the beginning" of cancer omics. In other words, each approach that was previously mentioned needs to be fully
understood as a part of a complex network, analyzing the mechanistic interplay of signaling 1 0 5
pathways, protein-protein interaction (PPi) networks, enrichment maps, gene ontology (GO), [23] [24] [25] [26] [27] [28] [29] . We will herein Commons of the National Cancer Institute and in the cBioPortal 45, 46 . In regard to molecular 1 4 2 subtypes and tumor stages, 46% were lumina A, 18% luminal B, 7% Her2-enriched, 16% basal-
like and 3% normal-like, whereas 17% were stage T1, 58% stage T2, 23% stage T3 and 2% 1 4 4
stage T4 (Table S1 ). frequency of the PCA gene set was 1.3, followed by CS gene set (1.2), PharmGKB/CGI gene clinical annotations in 14/230 (6%) genes (Table S35) 72 . Additionally, Figure S3 shows a drug-gene interaction matrix conformed by 109 clinical Administration (FDA), according to CGI; and 648 clinical annotations, according to PCA. In this study we proposed a compendium of OncoOmics approaches that analyze genetic ontology and dependency maps in three gene sets. The first gene set was taken from our previous study where we developed a Consensus Strategy that was proved to be highly efficient in the recognition of BC pathogenic genes 28 . The second gene set was taken from several studies of PCA, which provides a panoramic view of the oncogenic processes that contributes to BC 3 7 8 progression 3, 12, [30] [31] [32] [33] [34] [35] [36] . The third gene set was taken from the CGI and PharmGKB. On the one and taken from the NCCN, ESMO, CPNDS, DPWG and CPIC guidelines [41] [42] [43] [44] . Finally, the 3 8 2 compendium of these 230 potential essential genes in BC was analyzed through four different
OncoOmics approaches. The first OncoOmics approach consisted in the analysis of genetic alterations using the PCA 3 8 6 data 45, 46 . The frequency of genetic alterations in the CS (average = 1.2), PCA (1.3) and 3 8 7
PharmGKB/CGI (1.1) gene sets were higher than the non-cancer gene set (0.4) and the 3 8 8
previously known BC driver genes (0.8). This means that these 230 genes had a greater number of genetic alterations and might be strongly associated with BC ( Figure 1A ). The most common were basal-like, Her2-enriched, luminal B, normal-like and luminal A, whereas tumor stages
with the greatest number of genetic alterations were T2, T3, T1 and T4 . Genes
with the greatest number of genetic alterations per subtype were PIK3CA in luminal A, CCND1 3 9 5
in luminal B, TP53 in basal-like and normal-like, and ERBB2 in Her2-enriched (Figure 2A ),
whereas PIK3CA was the most altered gene in stage T1, TP53 in stages T2 and T3, and ERBB2 3 9 7
in stage T4 ( Figure 2B ). After a thorough analysis of genetic alterations in the 230 genes, the first OncoOmics approach Subsequently, the enrichment analysis of signaling pathways was carried on taking into account 4 0 6 all genetic alterations in the 230 genes using David Bioinformatics Resource and KEGG 47, 50 .
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The signaling pathways with the greatest number of genetic alterations per intrinsic molecular and T3, and thyroid hormone in stage T4 ( Figure 4D ). Regarding the previously mentioned signaling pathways, Jak-STAT is involved in the control of processes, such as stem cell maintenance, hematopoiesis and inflammatory response. However,
the mechanism underlying inappropriate Jak-STAT pathway activation is not well-known in showed a significant correlation between our String PPi network ( Figure 5A ) and the OncoPPi OncoOmics approach was made up with the top 40 genes with the highest degree centrality and were involved in tumor suppression processes. Lastly, genes with unfavorable prognosis in BC 4 6 0 were RAD51, PERP and MORC4 ( Figure 6 ) 55, 56 . The compendium of all these 60 proteins with 4 6 1 significant high and low expression made up the third OncoOmics approach. The fourth OncoOmics approach was related to the BC dependency map. According to
Tsherniak et al., the mutations that trigger the growth of cancer cells also confer specific
vulnerabilities that normal cells lack, and these dependencies are compelling therapeutic the greatest number of significant dependency scores in BC cell lines were RPL5, SF3B1, with the greatest number of significant dependencies in BC cell lines were RPA1, RRM1, ( Figure 7E ). EGFR, ABL1, RB1 and NOTCH1 ( Figure 8D ). essential genes in BC 83 . The most significant GO: biological process was the positive regulation of macromolecule metabolic process, the GO: molecular function was phosphatidylinositol 3-
kinase activity, the Reactome pathway was generic transcriptor pathway, and the most when the anti-PD-L1 antibody atezolizumab was approved to be used in combination with nab- The OTP is an available resource for the integration of genetics, omics and chemical data to aid kinases. Finally, the top ten genes with the greatest number of clinical trials in process or CGI is a platform that annotates clinical evidence and tumor variants that constitute state-of-art . Lastly, the drug-gene interaction matrix is a compendium of the most relevant clinical
annotations made up of 32 genes and 51 drugs in order to facilitate the treatment of patients
with BC ( Figure S3 ). In conclusion, since BC is a complex and heterogeneous disease, the study of different
OncoOmics approaches is an effective way to reveal essential genes to better understand the treatments focused on pharmacogenomics and precision medicine. Commons of the National Cancer Institute (https://gdc.cancer.gov/) and in the cBioPortal type, tumor stage and race/ethnicity. analyzed through exome sequencing, CNVs through the Genomic Identification of Significant
Targets in Cancer (GISTIC 2.0) 94, 95 , and mRNA expression through RNA Seq V2. We analyzed first gene set (n = 177) was integrated by the non-cancer genes 96 . We calculated the OncoScore
of non-cancer genes, taking out all genes from our study. The second gene set (n = 119) was the
BC driver genes, according to The Network of Cancer Genes 61 . The third gene set (n = 84) was
taken from our previous study where we developed a Consensus Strategy of prioritized genes
related to BC pathogenesis 28 . The fourth gene set (n = 85) was made up of genes associated with
BC development, according to several PCA studies 30, 31, 57 . The fifth gene set (n = 91) consisted
of BC biomarkers and druggable enzymes taken from PharmGKB and the CGI (Table S2) 37,38,40 .
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Finally, the significant differentiation of the average frequency of genetic alterations among
gene sets was analyzed (p-value < 0.001). The OncoOmics approaches were performed in 230 genes conformed by the CS, PCA and
PharmGKB/CGI gene sets. Firstly, we calculated the percentage and ratio of genetic alterations
per intrinsic molecular subtype and tumor stage, and we established a ranking of genes with the
greatest number of different genetic alterations. Subsequently, we performed an OncoPrint of
genes with more genetic alterations than the average. The final list of genes made up the first
OncoOmics approach. Pathway enrichment analysis. The enrichment analysis of signaling pathways was performed were stage T2, 113 were stage T3 and 103 were stage T4. Protein-protein interaction network. The PPi network with a highest confidence cutoff of 0.9
and zero node addition was created using the String Database, which takes into account
predicted and known interactions
51
. The confidence scoring is the approximate probability that a
predicted link exists between two enzymes in the same metabolic map, whereas the degree
centrality of a node means the number of edges the node has to other nodes in a network. The
centrality indexes calculation and network visualization were analyzed through the Cytoscape
software 52 . Genes with the highest degree centrality, consensus score and sub-networks were focused PPi analyzed in cell lines 28 . Lastly, genes with the highest degree centrality and
consensus scoring made up the second OncoOmics approach. Consortium (CPTAC), and it can be visualized in the cBioPortal 45, 46 . We analyzed the protein though the landscape of genetic alterations has been extensively studied to date, we have limited
understanding of the biological impact of these alterations in the development of specific tumor
vulnerabilities, which triggers a limited use of precision medicine in the clinical practice 6 2 7
worldwide. Therefore, the main goal of DepMap is to create a comprehensive preclinical cancer cell lines, whereas the CERES algorithm was applied to analyze genome-scale CRISPR-
Cas9 loss-of-function screens in 28 BC cell lines and 558 cancer cell lines 19, 21 . In addition to 6 3 7
existing cell lines, the Cancer Cell Line Encyclopedia (CCLE) project will greatly expand the Regarding dependency scores, a lower score means that a gene is more likely to be dependent in gives scientists curated interpretation of gene lists generated from genome-scale experiments 67 .
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